TRIL

Trillium Therapeutics Stock Price

12.20
-0.78 (-6.01%)
Upgrade to Real-Time
Afterhours (Closed)
12.20
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Trillium Therapeutics Inc TRIL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.78 -6.01% 12.20 19:53:58
Close Price Low Price High Price Open Price Previous Close
12.30 11.93 12.95 12.93 12.98
Bid Price Ask Price Spread News
12.20 12.25 0.05 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,595 1,577,035 $ 12.39 $ 19,542,015 1,714,857 0.2405 - 16.89
Last Trade Time Type Quantity Stock Price Currency
19:59:24 50 $ 12.25 USD

Trillium Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.08B 88.68M 12.35M $ - $ - -2.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Trillium Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TRIL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week14.8115.1411.9313.511,227,756-2.61-17.62%
1 Month13.7916.1511.9314.421,424,552-1.59-11.53%
3 Months6.7816.896.670113.182,214,6565.4279.94%
6 Months5.0616.894.2910.171,993,2957.14141.11%
1 Year0.279916.890.24055.992,558,10011.924,258.7%
3 Years7.3516.890.24055.211,065,2574.8565.99%
5 Years14.4617.700.24055.39676,094-2.26-15.63%

Trillium Therapeutics Description

Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer.


Your Recent History
NASDAQ
TRIL
Trillium T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.